DK3354734T3 - Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster - Google Patents

Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster Download PDF

Info

Publication number
DK3354734T3
DK3354734T3 DK18154472.7T DK18154472T DK3354734T3 DK 3354734 T3 DK3354734 T3 DK 3354734T3 DK 18154472 T DK18154472 T DK 18154472T DK 3354734 T3 DK3354734 T3 DK 3354734T3
Authority
DK
Denmark
Prior art keywords
oligonucleotide
comprehensive
nucleic acid
locked nucleic
based inhibitors
Prior art date
Application number
DK18154472.7T
Other languages
English (en)
Inventor
Rooij Eva Van
Christina Dalby
Rusty Montgomery
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Application granted granted Critical
Publication of DK3354734T3 publication Critical patent/DK3354734T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
DK18154472.7T 2012-06-21 2013-06-21 Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster DK3354734T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662746P 2012-06-21 2012-06-21
US201361801533P 2013-03-15 2013-03-15
EP13807536.1A EP2864482A4 (en) 2012-06-21 2013-06-21 OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN

Publications (1)

Publication Number Publication Date
DK3354734T3 true DK3354734T3 (da) 2020-06-29

Family

ID=49769732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18154472.7T DK3354734T3 (da) 2012-06-21 2013-06-21 Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster

Country Status (12)

Country Link
US (3) US9388408B2 (da)
EP (2) EP2864482A4 (da)
JP (2) JP6208228B2 (da)
KR (1) KR101928418B1 (da)
CN (2) CN104685056A (da)
AU (1) AU2013278011B2 (da)
CA (1) CA2876180C (da)
DK (1) DK3354734T3 (da)
ES (1) ES2801875T3 (da)
HK (2) HK1209781A1 (da)
MX (1) MX355408B (da)
WO (1) WO2013192576A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2652151A2 (en) * 2010-12-15 2013-10-23 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
UA115652C2 (uk) 2011-04-25 2017-12-11 Реґюлус Терап'Ютікс Інк. Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
AR090825A1 (es) 2012-04-25 2014-12-10 Regulus Therapeutics Inc COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP2757157A1 (en) * 2013-01-17 2014-07-23 Ecole Polytechnique Federale de Lausanne (EPFL) Modulation of mitophagy and use thereof
EP2968396B1 (en) * 2013-03-15 2018-12-19 Miragen Therapeutics, Inc. Locked nucleic acid inhibitor of mir-145 and uses thereof
CA2908939C (en) 2013-05-01 2023-08-22 Balkrishen Bhat Microrna compounds and methods for modulating mir-122
AU2015301221B2 (en) * 2014-08-04 2020-07-02 MiRagen Therapeutics, Inc. Inhibitors of MYH7B and uses thereof
CA2953883A1 (en) 2014-08-07 2016-02-11 Regulus Therapeutics Inc. Targeting micrornas for metabolic disorders
WO2016069717A1 (en) * 2014-10-28 2016-05-06 MiRagen Therapeutics, Inc. Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
KR20170103841A (ko) 2015-01-20 2017-09-13 미라젠 세러퓨틱스 인코포레이티드 Mir-92 억제제 및 이의 용도
US10538769B2 (en) 2015-09-04 2020-01-21 Oregon State University Renal selective inhibition of cytochrome P450 3A5
CN108025017A (zh) * 2015-09-22 2018-05-11 米拉根医疗股份有限公司 MiR-19调节剂及其用途
EP3985116A1 (en) * 2015-10-15 2022-04-20 City of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US10357543B2 (en) 2015-11-16 2019-07-23 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
CN105435247A (zh) * 2015-12-31 2016-03-30 中国医学科学院基础医学研究所 miR-378在预防和/或治疗肥胖症中的用途
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN106011140B (zh) * 2016-06-06 2018-12-18 同济大学 反义microRNA-25及其应用
WO2017214952A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用
WO2017214953A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
WO2017219165A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异敲低人 miRNA-29a 和 miR-140 表达的慢病毒载体及其应用
WO2017219166A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 一种同时抑制双 miRNA 表达的慢病毒载体及其应用
WO2018009855A1 (en) * 2016-07-07 2018-01-11 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
CN110141577A (zh) * 2018-02-13 2019-08-20 上海三炬生物科技有限公司 miRNA-24-3p核苷酸类似物在制备药物中的应用
EP3765619A4 (en) * 2018-03-14 2021-12-08 Beth Israel Deaconess Medical Center INHIBITORS OF MICRO-RNA 22
US20220056443A1 (en) * 2018-09-06 2022-02-24 Aptamir Therapeutics, Inc. Metabolic benefits of short mir-22 mirna antagomir therapies
CN110358769A (zh) * 2019-07-30 2019-10-22 中国医学科学院血液病医院(中国医学科学院血液学研究所) 经锁核酸和硫代磷酸修饰的miRNA类似物及其在制备抗肿瘤药物中的应用
CN110433170B (zh) * 2019-07-31 2021-04-27 南京医科大学 心脏抽吸液miR-28-5p在心脏疾病中的应用
US20220395587A1 (en) * 2019-11-15 2022-12-15 Duke University Cellular molecular theranostics nanoprobe systems and methods
CN111118008B (zh) * 2020-01-16 2023-08-22 南京医科大学 Mcl1基因的3’-UTR序列及其应用
WO2022018269A1 (en) * 2020-07-23 2022-01-27 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1995003843A1 (en) 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
HUP0102152A3 (en) 1998-05-26 2002-04-29 Icn Pharmaceuticals Inc Costa Nucleosid and oligo nucleotid analogues having bicyclic sugar derivative
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
KR20020007331A (ko) 1999-03-18 2002-01-26 추후제출 특이 ｌｎａ 프라이머에 의한 유전자중의 돌연변이 검출
AU7406600A (en) * 1999-10-04 2001-05-10 Exiqon A/S A method of increasing the specificity of oxy-lna oligonucleotides
US6998484B2 (en) 2000-10-04 2006-02-14 Santaris Pharma A/S Synthesis of purine locked nucleic acid analogues
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
JP4868739B2 (ja) 2002-05-06 2012-02-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 核酸の送達法
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
CA2506576C (en) 2002-11-18 2018-03-06 Santaris Pharma A/S Antisense gapmer oligonucleotides
EP2141234B1 (en) * 2003-03-21 2016-04-27 Roche Innovation Center Copenhagen A/S Short Interfering RNA (siRNA) Analogues
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
WO2005054494A2 (en) 2003-11-26 2005-06-16 University Of Massachusetts Sequence-specific inhibition of small rna function
WO2005078096A2 (en) 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
EP1713938A2 (en) 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005079397A2 (en) 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
WO2005082440A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
CA2572450A1 (en) 2004-05-28 2005-12-15 Ambion, Inc. Methods and compositions involving microrna
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
US9550990B2 (en) 2004-12-10 2017-01-24 Ionis Pharmaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
EP1874936B1 (en) 2005-04-19 2013-10-30 BASF Plant Science GmbH Improved methods controlling gene expression
ES2564823T3 (es) 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN
BRPI0619755A2 (pt) 2005-12-12 2011-10-18 Univ North Carolina micrornas que regulam a proliferação e diferenciação de células musculares
US20100286044A1 (en) 2005-12-29 2010-11-11 Exiqon A/S Detection of tissue origin of cancer
CA2640058C (en) 2006-01-27 2018-04-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EA015570B1 (ru) 2006-04-03 2011-10-31 Сантарис Фарма А/С Фармацевтическая композиция
US8466117B2 (en) 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
US8304397B2 (en) 2006-08-01 2012-11-06 Board Of Regents, The University Of Texas System Identification of a micro-RNA that activates expression of β-myosin heavy chain
US20090306181A1 (en) 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
EP2489742A1 (de) 2006-10-09 2012-08-22 Julius-Maximilians-Universität Würzburg MicroRNA (MIRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
EP2097527B1 (en) 2006-11-23 2018-08-01 Querdenker Aps Oligonucleotides for modulating target rna activity
US20100280094A1 (en) 2006-12-14 2010-11-04 Novartis Ag Compositions and methods to treat muscular & cardiovascular disorders
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
WO2008131191A2 (en) 2007-04-20 2008-10-30 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
EP2155911B1 (en) 2007-05-23 2013-08-28 Dharmacon, Inc. Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs
JP5654347B2 (ja) 2007-07-31 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ミオシンの発現及び筋線維の同一性を制御するマイクロｒｎａ
US20100292099A1 (en) 2007-08-23 2010-11-18 Keren Pharmaceutical, Inc. Targeting of rna with external guide sequences
AU2008298744B8 (en) 2007-09-14 2015-01-15 The Ohio State University Research Foundation MiRNA expression in human peripheral blood microvesicles and uses thereof
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
CN101424640B (zh) 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
JP5654352B2 (ja) 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
JP2011512326A (ja) 2007-12-31 2011-04-21 ナノコア セラピューティクス，インコーポレイテッド 心不全の治療用のｒｎａ干渉
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US20110160285A1 (en) 2008-03-13 2011-06-30 The Regents Of The University Of Colorado Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
WO2009151600A2 (en) 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
WO2010000665A1 (en) * 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
CN101386848A (zh) 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
EP2346883B1 (en) 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CN102356162A (zh) 2009-02-04 2012-02-15 得克萨斯系统大学董事会 Mir-208和mir-499在治疗心脏病症中的双重靶向
US9034837B2 (en) * 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
WO2010144485A1 (en) 2009-06-08 2010-12-16 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
DK2475372T4 (da) 2009-09-10 2020-11-30 Velin Pharma As Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US8592151B2 (en) 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
WO2011106442A1 (en) 2010-02-24 2011-09-01 The Board Of Trustees Of The Leland Stanford Junior University Control of cardiac growth, differentiation and hypertrophy
EP2550360B1 (en) 2010-03-24 2017-08-30 Mirrx Therapeutics A/s Bivalent antisense oligonucleotides
WO2011127625A1 (zh) 2010-04-13 2011-10-20 江苏命码生物科技有限公司 一种调节生物体内微小核糖核酸含量的方法及其用途
US9611511B2 (en) 2010-04-20 2017-04-04 Comprehensive Biomarker Center Gmbh Complex miRNA sets as novel biomarkers for an acute coronary syndrome
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130150256A1 (en) 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
ITMI20101089A1 (it) 2010-06-16 2011-12-17 Istituto Naz Di Genetica Molecolare Ingm Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario
EP2591095B1 (en) 2010-07-08 2016-04-27 Duke University Direct reprogramming of cells to cardiac myocyte fate
GB201012418D0 (en) * 2010-07-23 2010-09-08 Santaris Pharma As Process
WO2012018866A2 (en) 2010-08-03 2012-02-09 University Of South Alabama Methods and compositions for the diagnosis and treatment of breast cancer
WO2012020307A2 (en) 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
WO2012037254A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
EP2635681B8 (en) * 2010-11-05 2017-10-04 Miragen Therapeutics, Inc. Base modified oligonucleotides
EP2652151A2 (en) * 2010-12-15 2013-10-23 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
WO2012149646A1 (en) 2011-05-05 2012-11-08 Sunnybrook Research Institute Mirna inhibitors and their uses
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
GB201117482D0 (en) 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
WO2013059496A1 (en) 2011-10-18 2013-04-25 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
DK2790736T3 (da) 2011-12-12 2018-05-07 Oncoimmunin Inc In vivo levering af oligonukleotider
EP2604690A1 (en) 2011-12-15 2013-06-19 Oncostamen S.r.l. MicroRNAs and uses thereof
WO2013088338A1 (en) 2011-12-15 2013-06-20 Oncostamen S.R.L. Micrornas and uses therof
FR2984358A1 (fr) 2011-12-16 2013-06-21 Genethon Methodes pour le diagnostic de dystrophies musculaires
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
ES2606636T3 (es) 2013-01-24 2017-03-24 Pierre Fabre Médicament S.A.S. Composición que comprende un antagomir encapsulado
KR20170103841A (ko) 2015-01-20 2017-09-13 미라젠 세러퓨틱스 인코포레이티드 Mir-92 억제제 및 이의 용도

Also Published As

Publication number Publication date
CA2876180C (en) 2019-11-19
MX2014015643A (es) 2015-07-17
EP3354734A1 (en) 2018-08-01
KR20150023687A (ko) 2015-03-05
CN104685056A (zh) 2015-06-03
JP2017217007A (ja) 2017-12-14
AU2013278011B2 (en) 2018-09-20
KR101928418B1 (ko) 2018-12-12
JP6208228B2 (ja) 2017-10-04
US9803202B2 (en) 2017-10-31
EP3354734B1 (en) 2020-06-10
US10337005B2 (en) 2019-07-02
EP2864482A4 (en) 2016-02-10
US20160326526A1 (en) 2016-11-10
MX355408B (es) 2018-04-18
WO2013192576A2 (en) 2013-12-27
WO2013192576A3 (en) 2014-04-03
US20180273944A1 (en) 2018-09-27
HK1244509A1 (zh) 2018-08-10
AU2013278011A1 (en) 2015-01-15
CA2876180A1 (en) 2013-12-27
EP2864482A2 (en) 2015-04-29
US20130344135A1 (en) 2013-12-26
JP2015521626A (ja) 2015-07-30
HK1209781A1 (en) 2016-04-08
CN107236735B (zh) 2019-11-08
ES2801875T3 (es) 2021-01-14
CN107236735A (zh) 2017-10-10
US9388408B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
DK3354734T3 (da) Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster
HRP20181862T1 (hr) Inhibitori dna-pk
SMT201700109B (it) Inibitori di istone demetilasi
DK2895484T3 (da) Glucosylceramidsynthase-inhibitorer
SMT201600114B (it) Inibitori di beta-secretasi
HK1226105B (zh) 核酸測序的改進方法
EP2917372A4 (en) NUCLEIC ACID SEQUENCING USING LABELS
BR112014009066A8 (pt) dna triciclo-fosforotioato
FI20125861A (fi) Tiivistetty pipetti
SG10201802883UA (en) Nucleic acid amplification
HK1211988A1 (en) Multiphase nucleic acid amplification
EP2915815A4 (en) NEW MODIFIED NUCLEIC ACID
DK2708607T3 (da) Genetiske markører for Myb28
FI20125137A (fi) Prosessikalibraattori
DK3427723T3 (da) Rna-formulering til immunterapi
FR2997080B1 (fr) Inhibiteurs de neprilysine
TH1401002448B (th) สารยับยั้ง dpp-4
TH148762B (th) อนุพันธ์ของพิร์โรลิดีน-3-อิลแอซีติก แอซิด
UA25647S (uk) Комплект етикеток
UA24571S (uk) Комплект етикеток
UA24351S (uk) Комплект етикеток
UA24094S (uk) Комплект етикеток
UA24078S (uk) Комплект етикеток
UA25261S (uk) Чуні сталеварні
UA22989S (uk) Комплект етикеток